05/19/2026
In our R&D and biopharma ecosystem of cc-TDI and , we congratulate Xiaolei Lian on his study of a tool ADC targeting the IL-13 receptor in the childhood brain tumor, DIPG. As mentioned in the paper, a different and in-licensed antibody is being pursued via the Artisan pipeline, but Xiaolei's paper gives proof-of-concept for the target (IL-13 receptor) and the payload type (a topoisomerase inhibitor). This therapeutic approach was born in an international collaboration we coordinated from the Children's Oncology Group brain tumor committee (a massive effort described in a Scientific American article, https://www.scientificamerican.com/article/scientists-tackle-lethal-childhood-brain-cancer).
In Xiaolei's newly-published studies, cc-TDI lab team members include Samuel, Victoria, Shefali, Guak-Kim and Noah, as well as interns Paige, Kyle and Emily. Collaborators included Drs. Hoshino, Liu and Lian. Artisan CSO, Dr. Tony Haight is also a key contributor and co-author. This work was funded by The Lyla Nsouli Foundation for Children's Brain Cancer Research, IronMattLarson, Hero Up Half Marathon, and young Ryan McGuire in affiliation with . We thank Tim Brown and Emma Lashyro for support in the design and ex*****on of studies.
